Early Planning & Modelling

  • Parexel Simplifies Access to Knowledge2:48

    Parexel Simplifies Access to Knowledge

    A new report by the Economist Intelligence Unit (EIU) and commissioned by Parexel International Corporation reveals that new innovations in drug development have a positive impact on clinical trial ti

    Watch Video
  • See how our experts can add value to your strategy

    Learn More ►
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Get your free evidence readiness score today!

    Take Assessment
  • The Increasingly Important Role of Real-World Evidence in CE modeling

    The Increasingly Important Role of Real-World Evidence in CE modeling

    The methods used to estimate cost-effectiveness of health technologies are constantly evolving. Early approaches in economic evaluation for health technologies relied primarily on the use of evidence.

    Read More
  • Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?

    Innovative Clinical Trial Designs — Welcomed By Regulators But What About The Payers?

    View Now
  • Presentation Slides: Early Engagement Strategies Webinar

    Presentation Slides: Early Engagement Strategies Webinar

    View Now
  • Promoting the patient voice in evidence generation and global market-access planning

    Promoting the patient voice in evidence generation and global market-access planning

    Presentation from the Medical Affairs Leaders Forum, London. February 27 - March 01, 2018

    View Now
  • Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Read More
  • The UK Early Access to Medicines Scheme: A 2-Year Status Update On Success, Issues and Controversies

    The UK Early Access to Medicines Scheme: A 2-Year Status Update On Success, Issues and Controversies

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Treatment Efficacy in Sequence Modelling - A Review of Published Approaches

    Treatment Efficacy in Sequence Modelling - A Review of Published Approaches

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Integrated Development Is How You Win Approval, Reimbursement And Differentiation

    Integrated Development Is How You Win Approval, Reimbursement And Differentiation

    View Now
  • Nice's Criteria for End-Of-Life Therapies: Is There a Fourth Hurdle to Overcome?

    Nice's Criteria for End-Of-Life Therapies: Is There a Fourth Hurdle to Overcome?

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Is There Evidence of a Difference Between Willingness to Pay and Willingness to Accept Thresholds? A Review of Nice Technology Appraisals

    Is There Evidence of a Difference Between Willingness to Pay and Willingness to Accept Thresholds? A Review of Nice Technology Appraisals

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Extrapolation of Time-To-Event Data in Various Disease Areas: Current Recommendations and Gaps

    Extrapolation of Time-To-Event Data in Various Disease Areas: Current Recommendations and Gaps

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Evidence of Value: How to Build A Robust Argument

    Evidence of Value: How to Build A Robust Argument

    Learn more about how to achieve regulatory and payer approval for drug discovery here!

    View Now
  • Considerations in Biosimilars Development – A US FDA Perspective

    Considerations in Biosimilars Development – A US FDA Perspective

    Read this presentation to find out more!

    Read More
  • loading
    Loading More...